Scaling up human papillomavirus vaccination: A conceptual framework of vaccine adherence

Sexual Health

Volumn 7, Issue 3, 2010, Pages 279-286

  Katz, Ingrid T ^a,b   Ware, Norma C ^b   Gray, Glenda ^c   Haberer, Jessica E ^b,d,g   Mellins, Claude A ^f   Bangsberg, David R ^b,d,e,g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^g Harvard Initiative for Global Health   (United States)

Author keywords

adolescents; development; sexually transmissible infection

Indexed keywords

WART VIRUS VACCINE;

AUSTRALIA; BEHAVIOR; CONCEPTUAL FRAMEWORK; CULTURAL FACTOR; DEATH; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE PREDISPOSITION; FAMILY; HEALTH BELIEF; HIGH RISK POPULATION; HUMAN; INFECTION RISK; NONHUMAN; PARENTAL ATTITUDE; PATIENT COMPLIANCE; POPULATION; PUBLICATION; REVIEW; SEXUALLY TRANSMITTED DISEASE; SOCIAL CLASS; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; VACCINATION; VIRUS STRAIN; WART VIRUS;

ADOLESCENT; CHILD; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; HEALTH EDUCATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PLAN IMPLEMENTATION; HUMANS; MASS VACCINATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; SEXUALLY TRANSMITTED DISEASES, VIRAL; UTERINE CERVICAL NEOPLASMS;

EID: 77956015851     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH09130     Document Type: Review

References (86)

1. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24: 1-10.
2. Baden LR, Curfman GD, Morrissey S, Drazen JM. Human papillomavirus vaccine - opportunity and challenge. N Engl J Med 2007; 356: 1990-1991 doi:10.1056/NEJMe078088 (Pubitemid 46740310)
3. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527 doi:10.1056/NEJMoa021641 (Pubitemid 36159887)
4. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044 doi:10.1002/ ijc.21731
5. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi F. Carcinogenicity of human papillomavirus. Lancet Oncol 2005; 6: 204. doi:10.1016/S1470-2045(05)70086-3 (Pubitemid 40450709)
6. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/ 18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-339 doi:10.1093/jnci/djp534
7. Myers E, Huh WK, Wright JD, Smith JS. The current and future role of screening in the era of HPV vaccination. Gynecol Oncol 2008; 109 (Suppl 1): S31-9. doi:10.1016/j.ygyno.2008.02.001 (Pubitemid 351658943)
8. Padian NS, Buvé A, Balkus J, Serwadda D, Cates W Jr. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008; 372: 585-599 doi:10.1016/S0140-6736(08) 60885-5
9. Lehmann C, Benson PA. Vaccine adherence in adolescents. Clin Pediatr 2009; 48: 801-811 doi:10.1177/0009922809336360
10. Heininger U, Loos K, Lorenz I, Rascher W. Compliance with recommended immunizations in adolescents. Eur J Pediatr 2006; 165: 671-676 doi:10.1007/s00431-006-0161-9 (Pubitemid 44310292)
11. Nelson JC, Bittner RC, Bounds L, Zhao S, Baggs J, Donahue JG, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health 2009; 99(Suppl 2): S389-97.doi:10.2105/AJPH.2008.151332
12. Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1- positive adults. Int J Infect Dis 2008; 12: e77-83. doi:10.1016/ j.ijid.2008.05.1226
13. Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B. Chapter 24: psychosocial aspects of vaccine acceptability. Vaccine 2006; 24(Suppl 3): S201-9. doi:10.1016/j.vaccine.2006.06.017 (Pubitemid 44308673)
14. Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E. Costeffectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico. Arch Med Res 2009; 40: 503-513 doi:10.1016/ j.arcmed.2009.08.004
15. Ault K, Reisenger K. Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer. Int J Infect Dis 2007; 11(Suppl 2): S26-8. doi:10.1016/S1201-9712(07)
16. Goldie SJ, O'Shea M, Diaz M, Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008; 16: 86-96. doi:10.1016/S0968-8080(08) 32409-4
17. Zimet GD, Mays RM,Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med 2000; 9: 47-50. doi:10.1089/152460900318957 (Pubitemid 30148102)
18. de Bruyn G, Skhosana N, Robertson G, McIntyre JA, Gray GE. Knowledge and attitudes towards HIV vaccines among Soweto adolescents. BMC Res Notes 2008; 1: 76. doi:10.1186/1756-0500-1-76
19. Fazekas KI, Brewer NT, Smith JS. HPV vaccine acceptability in a rural Southern area. J Womens Health 2008; 17: 539-548 doi:10.1089/jwh.2007.0489 (Pubitemid 351630156)
20. Brabin L, Roberts SA, Stretch R, Baxter D, Chambers G, Kitchener H, et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 2008; 336: 1056-1058 doi:10.1136/bmj.39541.534109.BE (Pubitemid 351692248)
21. Garland SM, Brotherton JM, Skinner SR, Pitts M, Saville M, Mola G, et al. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention. Vaccine 2008; 26(Suppl 12): M80-8. doi:10.1016/j.vaccine.2008.05.041
22. Garland SM. Can cervical cancer be eradicated by prophylactic HPV vaccination? Challenges to vaccine implementation. Indian J Med Res 2009; 130: 311-321
23. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85: 499-502. doi:10.1136/sti.2009.037788
24. Conroy K, Rosenthal SL, Zimet GD, Jin Y, Bernstein DI, Glynn S, et al. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Womens Health 2009; 18: 1679-1686 doi:10.1089/jwh.2008.1329
25. Sturm LA, Mays RM, Zimet GD. Parental beliefs and decision making about child and adolescent immunization: from polio to sexually transmitted infections. J Dev Behav Pediatr 2005; 26: 441-452 doi:10.1097/00004703- 200512000-00009 (Pubitemid 44384155)
26. Mok E, Yeung SH, Chan MF. Prevalence of influenza vaccination and correlates of intention to be vaccinated among Hong Kong Chinese. Public Health Nurs 2006; 23: 506-515 doi:10.1111/j.1525-1446. 2006.00590.x
27. Daley MF, Crane LA, Chandramouli V, Beaty BL, Barrow J, Allred N, et al. Influenza among healthy young children: changes in parental attitudes and predictors of immunization during the 2003 to 2004 influenza season. Pediatrics 2006; 117: e268-77. doi:10.1542/peds. 2005-1752
28. Marlow LA, Waller J, Evans RE, Wardle J. Predictors of interest in HPV vaccination: a study of British adolescents. Vaccine 2009; 27: 2483-2488 doi:10.1016/j.vaccine.2009.02.057
29. Reiter PL, Brewer NT, Gottlieb SL, McRee AL, Smith JS. How much will it hurt? HPV vaccine side effects and influence on completion of the three-dose regimen. Vaccine 2009; 27: 6840-6844 doi:10.1016/ j.vaccine.2009.09.016
30. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries - key challenges and issues. N Engl J Med 2007; 356: 1908-1910 doi:10.1056/NEJMp078053 (Pubitemid 46740300)
31. Wong LP. Physicians experiences with HPV vaccine delivery: evidence from developing country with multiethnic populations. Vaccine 2009; 27: 1622-1627 doi:10.1016/j.vaccine.2008.11.107
32. Winkler JL, Wittet S, Bartolini RM, Creed-Kanashiro HM, Lazcano- Ponce E, Lewis-Bell K, et al. Determinants of human papillomavirus vaccine acceptability in Latin America and the Caribbean. Vaccine 2008; 26(Suppl 11): L73-9. doi:10.1016/j.vaccine.2008.05.027
33. Muñoz N, Franco EL, Herrero R, Andrus JK, de Quadros C, Goldie SJ, et al. Recommendations for cervical cancer prevention in Latin America and the Caribbean. Vaccine 2008; 26(Suppl 11): L96-107. doi:10.1016/j.vaccine.2008.05. 062
34. Andrus JK, Sherris J, Fitzsimmons JW, Kane MA, Aguado MT. Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement. Vaccine 2008; 26(Suppl 10): K87-92. doi:10.1016/j.vaccine.2008. 05.003
35. Gauri V, Khaleghian P. Immunization in developing countries: its political and organizational determinants. Policy Research Working Paper 2769. World Development 2002; 30: 2109-2132
36. Loevinsohn B, Hong R, Gauri V. Will more inputs improve the delivery of health services? Analysis of district vaccination coverage in Pakistan. Int J Health Plann Manage 2006; 21: 45-54. doi:10.1002/hpm.824
37. Harries J, Moodley J, Barone MA, Mall S, Sinanovic E. Preparing for HPV vaccination in South Africa: key challenges and opinions. Vaccine 2009; 27: 38-44. doi:10.1016/j.vaccine.2008.10.033
38. de Bruyn G, Skhosana N, Robertson G, McIntyre JA, Gray GE. Knowledge and attitudes towards HIV vaccines among Soweto adolescents. BMC Res Notes 2008; 1: 76. doi:10.1186/1756-0500-1-76
39. Sayles JN, Macphail CL, Newman PA, Cunningham WE. Future HIV vaccine acceptability among young adults in South Africa. Health Educ Behav 2010; 37: 193-210. doi:10.1177/1090198109335654
40. Kalijee LM, Pack R, Pach A, Nyamete A, Stanton BF. Sociobehavioural research methods for the introduction of vaccines in the diseases of the most impoverished programme. J Health Popul Nutr 2004; 22: 293-303.
41. Sherris J, Friedman A, Wittet S, Davies P, Steben M, Saraiya M. Chapter 25: education, training, and communication for HPV vaccines. Vaccine 2006; 24(Suppl 3): S210-8. doi:10.1016/j.vaccine. 2006.05.124
42. Andrus JK, Lewis MJ, Goldie SJ, Garcia PJ, Winkler JL, Ruiz-Matus C, et al. Human papillomavirus vaccine policy and delivery in Latin America and the Caribbean. Vaccine 2008; 26: L80-7. doi:10.1016/ j.vaccine.2008.05.040
43. Bonanni P, Boccalini S, Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 2009; 27(Suppl 1): A46-53. doi:10.1016/j.vaccine.2008. 10.085
44. Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26: 6844-6851 doi:10.1016/j.vaccine.2008.09.073
45. Watson M, Shaw D, Molchanoff L, McInnes C. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust NZ J Public Health 2009; 33: 365-370 doi:10.1111/j.1753- 6405.2009.00409.x
46. Centers for Disease Control and Prevention. Vaccination coverage among adolescents aged 13-17 years - United States, 2007. MMWR Morb Mortal Wkly Rep 2008; 57: 1100-1103
47. Chao C, Slezak JM, Coleman KJ, Jacobsen SJ. Papanicolaou screening behavior in mothers and human papillomavirus vaccine uptake in adolescent girls. Am J Public Health 2009; 99: 1137-1142 doi:10.2105/AJPH.2008.147876
48. Neubrand TP, Radecki-Breitkopf C, Rupp R, Brieitkopf D, Rosenthal SL. Factors associated with completion of the human papillomavirus vaccine series. Clin Pediatr 2009; 48: 966-9. doi:10.1177/ 0009922809337534
49. Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol 2008; 111: 1103-1110
50. Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine 2010; 28: 989-995 doi:10.1016/j.vaccine. 2009.10.133
51. Rots NY, Wijmenga-Monsuur AJ, Luytjes W, Kaaijk P, de Graaf TW, van der Zeijst BAM, et al. Hepatitis B vaccination strategies tailored to different endemicity levels: some considerations. Vaccine 2010; 28: 893-900. doi:10.1016/j.vaccine.2009.10.125
52. Sneller VP, Fishbein DB, Weinbaum CM, Lombard A, Murray P, McLaurin JA, et al. Working Group on Vaccination of High-Risk Adolescents. Vaccinating adolescents in high-risk settings: lessons learned from experiences with hepatitis B vaccine. Pediatrics 2008; 121: S55-62. doi:10.1542/peds.2007-1115G
53. Geber GM. Barriers to health care for street youth. J Adolesc Health 1997; 21: 287-290 doi:10.1016/S1054-139X(97)00111-0 (Pubitemid 27459527)
54. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-1355 doi:10.1093/jnci/djp288
55. Boland G, Beran J, Lievens M, Sasadeusz J, Dentico P, Nothdurft H, et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 2004; 23: 316-320 doi:10.1016/j.vaccine.2004.06. 006 (Pubitemid 39463048)
56. Heron L, Selnikova O, Moiseieva A, Van Damme P, van der Wielen M, Levie K, et al. Immunogenicity, reactogenicity and safety of twodose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial. Vaccine 2007; 25: 2817-2822 doi:10.1016/j.vaccine.2006.12.021 (Pubitemid 46412571)
57. Altice FL, Bruce RD, Walton MR, Buitrago MI. Adherence to hepatitis B virus vaccination at syringe exchange sites. J Urban Health 2005; 82: 151-161 doi:10.1093/jurban/jti016 (Pubitemid 41214137)
58. Lum PJ, Hahn JA, Shafer KP, Evans JL, Davidson PJ, Stein E, et al. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J Viral Hepat 2008; 15: 229-236
59. Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT. A brief report: country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 2008; 26: 6529-6541 doi:10.1016/j.vaccine.2008.08.067
60. Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007; 85: 719-726 doi:10.2471/BLT.06. 038414
61. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8. doi:10.1016/S1470-2045 (05)70101-70107
62. Bloom B, Cohen RA. Summary health statistics for US children: National Health Interview Survey. 2006. Vital Health Stat 10 2007; 234: 1-79.
63. Harries J, Moodley J, Barone MA, Mall S, Sinanovic E. Preparing for HPV vaccination in South Africa: key challenges and opinions. Vaccine 2009; 27: 38-44. doi:10.1016/j.vaccine.2008.10.033
64. Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004; 23: 1035-1041 doi:10.1097/01. inf.0000143646.15240.ac
65. Bingham A, Drake JK, LaMontagne DS. Socio-cultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch Pediatr Adolesc Med 2009; 163: 455-461 doi:10.1001/archpediatrics.2009.50
66. Rosenthal SL, Kottenhahn RK, Biro FM, Succop PA. Hepatitis B acceptance among adolescents and their parents. J Adolesc Health 1995; 17: 248-254 doi:10.1016/1054-139X(95)00164-N
67. Ford CA, English A, Davenport AF, Stinnett AJ. Increasing adolescent vaccination: barriers and strategies in the context of policy, legal, and financial issues. J Adolesc Health 2009; 44: 568-574 doi:10.1016/j.jadohealth. 2008.11.015
68. Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med 2009; 6: e11. doi:10.1371/journal.pmed.1000011
69. Williams GC, Niemiec CP, Patrick H, Ryan RM, Deci EL. The importance of supporting autonomy and perceived competence in facilitating long-term tobacco abstinence. Ann Behav Med 2009; 37: 315-324 doi:10.1007/s12160-009-9090-y
70. Bogart LM, Delahanty DL. Psychological models. In Boll TJ, Frank RC, Baum A, Wallander JL, editors. Handbook of clinical health psychology. vol 3. Models and perspectives in health psychology. Washington DC: American Psychological Association; 2004. pp. 249-289
71. Fishbein M, Azjen I. Belief, attitude, intention and behavior: an introduction to theory and research. Reading, MA: Addison- Wesley; 1975.
72. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007; 45: 107-114 doi:10.1016/j.ypmed.2007.05.013 (Pubitemid 47348081)
73. Becker MH. The health belief model and personal health behavior. Health Educ Monogr 1974; 2: 324-508.
74. Brewer NT, Chapman GB, Gibbons FX, Gerard M, McCaul KD, Weinstein ND. A meta-analysis of the relationship between risk perception and health behavior: the example of vaccination. Health Psychol 2007; 26: 136-145 doi:10.1037/0278-6133.26.2.136 (Pubitemid 46494598)
75. Sales JM, Milhausen RR, Wingood GM, DiClemente RJ, Salazar LF, Crosby RA. Validation of a parent-adolescent communication scale for use in STD/HIV prevention interventions. Health Educ Behav 2008; 35: 332-345 doi:10.1177/1090198106293524
76. Gerend MA, Shepherd JE. Using message framing to promote acceptance of the human papillomavirus vaccine. Health Psychol 2007; 26: 745-752 doi:10.1037/0278-6133.26.6.745 (Pubitemid 350161074)
77. Hilton S, Hunt K, Langan M, Bedford H, Petticrew M. Newsprint media representations of the introduction of the HPV vaccination programme for cervical cancer prevention in the UK (2005-2008). Soc Sci Med 2010; 70: 942-950 doi:10.1016/j.socscimed.2009.11.027
78. Abdelmutti N, Hoffman-Goetz L. Risk messages about HPV, cervical cancer, and the HPV vaccine Gardasil: a content analysis of Canadian and U.S. national newspaper articles. Women Health 2009; 49: 422-440 doi:10.1080/03630240903238776
79. Newman PA, Lee SJ, Duan N, Rudy E, Nakazono TK, Boscardin J, et al. Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES). Health Serv Res 2010; 44: 2167-2179 doi:10.1111/j.1475-6773.2009.01039.x
80. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-2220 doi:10.1056/NEJMoa0908492
81. Weiss RA. On viruses, discovery, and recognition. Cell 2008; 135: 983-986 doi:10.1016/j.cell.2008.11.022
82. UNAIDS. AIDS epidemic update. Geneva: Joint United Nations Programme on HIV/AIDS; 2007.
83. IAVI Publications. Current HPV vaccines and future AIDS vaccines: common challenges and unprecedented opportunities. New York: IAVI; 2008. Available online at: pages/publicationdetail.aspx?pubid=15af74c1-c0b1-4a9ba87a- 8dec767740d2 [verified November 2009]
84. Heise LL, Elias C. Transforming AIDS prevention to meet womens needs: a focus on developing countries. Soc Sci Med 1995; 40: 931-943 doi:10.1016/0277-9536(94)00165-P
85. dCruz-Grote D. Prevention of HIV infection in developing countries. Lancet 1996; 348: 1071-1074 doi:10.1016/S0140-6736(95)11031-3 (Pubitemid 26343604)
86. Esparza J, Osmanov S, Pattou-Markovic C, Toure C, Chang ML, Nixon S. Past, present and future of HIV vaccine trials in developing countries. Vaccine 2002; 20: 1897-1898 doi:10.1016/S0264-410X(02) 00062-2